• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Brintellix Bring Anything New?

Does Brintellix Bring Anything New?

November 1, 2013
Steve Balt, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Steve Balt, MD Research fellow, Addiction Pharmacology Research Laboratory, California Pacific Medical Center Dr. Balt discloses that his spouse is employed as a sales representative for Bristol Myers Squibb.

After a dry spell of new antidepressants—the last one to be approved was levomilnacipran (Fetzima), the active enantiomer of milnacipran (Savella) in July 2013—the FDA approved vortioxetine (Brintellix) in September. Vortioxetine is another serotonergic antidepressant. How exactly does it work, and what are its advantages over existing drugs?

Vortioxetine has several actions on serotonin-related targets. Like SSRIs, it’s a serotonin reuptake inhibitor. It’s also an agonist at 5-HT1A receptors as well as an antagonist of 5-HT3A and 5-HT7 receptors. (You may recall that buspirone (BuSpar), vilazodone (Viibryd), and aripiprazole (Abilify) are partial agonists of this receptor, among other functions.)

Thus, it sounds promising, but receptor-binding properties usually confer advantages that are only theoretical in nature. Therefore, a look at the data is appropriate.

Approval of vortioxetine was based on six short-term (6- to 8-week) studies of vortioxetine compared against placebo and/or duloxetine (Cymbalta) or venlafaxine (Effexor). These studies revealed that the effective doses of vortioxetine range from 5 to 20 mg/day, and also that vortioxetine was roughly similar in efficacy to venlafaxine but worse than duloxetine.

Other failed trials have been published, which generally used lower doses of vortioxetine (although some trials showed failure even at higher doses of 10 mg/day or 15 mg/day). A European trial found vortioxetine to be superior to agomelatine, an antidepressant whose manufacturer has not submitted it for FDA approval in the US due to lack of efficacy. As of summer 2013, there were 33 studies of vortioxetine registered with www.clinicaltrials.gov, for a range of diagnoses, so more data should be emerging.

In a longer-term trial, vortioxetine was found to be effective in preventing relapse in a 52-week study of adults with depression, although doses were low (2.5 to 10 mg/day) and the study was open-label, with no placebo control. A short-term trial in elderly patients (ages 65 and older) also found it similar in efficacy to duloxetine.

The advantages of vortioxetine over existing agents remain to be seen. One possible advantage, which is already being discussed in the literature, is a “pro-cognitive” benefit due to its 5-HT7 antagonist properties. Compounds with this property have shown some benefit in animal models of learning and memory. Existing data in humans are minimal. As for side effects, the most common was dose-related nausea (reported by roughly 25% of subjects), while weight gain was negligible.

TCPR’s Verdict: Vortioxetine might be more than just a “me-too” drug, as its pharmacodynamic properties are slightly different from any existing agent on the market. But the data demonstrate no clear advantages over currently available drugs, and its cost is likely to be substantially higher than what’s available now. Further head-to-head trials with other antidepressants, as well as specific studies on purported advantages of vortioxetine, for example, in cognition, are necessary.
General Psychiatry
KEYWORDS antidepressants depressive_disorder
    Balt 150x150
    Steve Balt, MD

    Four Newer Antidepressants: Should You Use Them?

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2013
    SUBSCRIBE NOW
    Table Of Contents
    Fire in the Mind: The Depression-Inflammation Connection
    Clinical Trials: Show Us the Data
    Does Brintellix Bring Anything New?
    Metformin for Weight Loss in Schizophrenia
    Ketamine for Depression
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.